ANTX AN2 Therapeutics, Inc.
Price Chart
Executive Summary
AN2 Therapeutics reported positive enabling data for its oral CPSF3 inhibitor AN2-502998 in chronic Chagas disease. A 28-day NHP study achieved 100% parasite elimination at human-attainable exposures, durable through 4 months post-treatment, and the Phase 1 FIH study showed a favorable safety profile with no dose-limiting toxicities. The company plans to initiate a Phase 2 study late 2026 and highlights a multi-billion-dollar global market opportunity with potential FDA Priority Review Voucher eligibility.
Actionable Insight
The data represents a significant derisking catalyst for AN2-502998, a potential first-in-class oral treatment for a large unmet need market. Monitor for initiation of the Phase 2 study late 2026 and any partnership or financing announcements. The stock may re-rate on the NHP efficacy and safety profile, but binary clinical risk remains.
Key Facts
- 100% of treated NHPs achieved parasite elimination at target exposures attainable in humans after 28 days of AN2-502998.
- Parasite elimination was durable and maintained through 4 months following end of treatment.
- Phase 1 FIH study showed AN2-502998 was generally well tolerated with no dose-limiting toxicities; human PK at or above NHP efficacy thresholds.
- AN2-502998 is the only compound to have demonstrated curative activity in NHPs with naturally acquired chronic T. cruzi infection.
- No FDA-approved treatments exist for adults with chronic Chagas disease; over 300,000 infected in the U.S., ~10M globally.
- Company plans to initiate a Phase 2 proof-of-concept study late 2026 in collaboration with DNDi.
- Potential multi-billion-dollar market opportunity and eligibility for FDA Tropical Disease Priority Review Voucher.
Financial Impact
No financial figures provided; company highlights a potential multi-billion-dollar global market opportunity for Chagas disease, but no actual revenue, EPS, or deal values are disclosed.
Risk Factors
- Preclinical NHP data may not predict human trial outcomes; Phase 2 proof-of-concept results expected late 2026 or later.
- Company will need additional capital to fund Phase 2 and beyond; dilution risk remains.
- Regulatory path for Chagas disease is undefined; no FDA-approved adult treatment exists, creating precedent uncertainty.
- Commercial opportunity is based on company estimates and market analogy to hepatitis C, which may not materialize.
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-257430 |
| Document: d247428dex991.htm | 0001193125-26-257430 |
| Document: 0001193125-26-257430-index-headers.html | 0001193125-26-257430 |
| Document: 0001193125-26-257430-index.html | 0001193125-26-257430 |
| Document: 0001193125-26-257430.txt | 0001193125-26-257430 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 4, 2026
8d ago
|
8-K
| $4.19 awaiting T+20 | awaiting T+20 | — | $4.74 (+13.13%) |
|
Apr 22, 2026
7w ago
|
DEFA14A
| $4.28 $4.59 | ▲ +7.24% | ▲ +2.61% | $4.74 (+10.75%) |
|
Apr 21, 2026
7w ago
|
EFFECT
| $3.80 $4.48 | ▲ +17.89% | ▲ +12.98% | $4.74 (+24.74%) |
|
Apr 20, 2026
7w ago
|
424B5
| $3.80 $4.48 | ▼ −17.89% | ▼ −12.98% | $4.74 (−24.74%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access